AstraZeneca PLC (AZN) Competitors & Peers
The 5 largest companies in the same industry as AstraZeneca PLC, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Peer | $1,422.89 | P/E 46.2RSI 68Cap 1.34 T |
| JNJ | Peer | $281.02 | P/E 42.6RSI 62Cap 676.5 B |
| ABBV | Peer | $293.51 | P/E 50.4RSI 60Cap 518.6 B |
| MRK | Peer | $146.82 | P/E 148.3RSI 51Cap 362.6 B |
| NVS | Peer | $163.29 | P/E 31.2RSI 66Cap 311.6 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- MRNASupplier
Own 10-K customer-concentration disclosure: AstraZeneca = 34% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - INOSupplier
Own 10-K customer-concentration disclosure: AstraZeneca = 2% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - NKTRSupplier
Own 10-K customer-concentration disclosure: AstraZeneca = 29% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - RIGLSupplier
Own 10-K customer-concentration disclosure: AstraZenecaAB = 100% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- DSNKYPartner
AZN + Daiichi Enhertu + datopotamab DXd-ADC collaboration.
Model-inferred, unverified — treat as a lead, not evidence - DNTHCompetitor
Dianthus' DNTH103 competes with AstraZeneca's Soliris/Ultomiris products.
Model-inferred, unverified — treat as a lead, not evidence